Get our latest issue now

available for iOS, Android & web

latest issue

Mylan launches 18 HIV drugs in India

Daily News | August 07, 2012

Kevin Grogan

Mylan launches 18 HIV drugs in India

Days after linking up with Gilead Sciences to make cheap HIV generics, Mylan has started commercial operations in India with the launch of 18 antiretrovirals for the treatment of the disease.

The US generics major notes that India is home to the world's third largest population of people with HIV/AIDS, with 2.4 million people living with the disease, of which fewer than 20% have access to treatment. Mylan says it will have one of the largest field forces exclusively specialising in HIV/AIDS in India.

Mylan chief executive Heather Bresch said the firm "can set a new standard in the treatment of HIV/AIDS in India by providing healthcare providers and those living with the disease access to high quality, affordable medicines and by supporting physicians in their efforts to educate and treat their patients". She added that "we see significant growth potential in India, the world's second largest pharmaceutical market by volume, and look forward to continuing to expand our operations in India in additional therapeutic categories".

In August 2006. Mylan spent about $736 million for an up-to-71.5% stake in Indian drugmaker Matrix Laboratories and went on to fully acquire the Hyderabad-based group. Last week, Mylan and Indian drugmakers Ranbaxy Laboratories and Strides Arcolab signed a deal with Gilead Sciences to promote access to "high-quality, low-cost generic versions" of the US firm's HIV drug Emtriva (emtricitabine) in developing countries.

Click here to order a reprint of this news story.


Your Comments

Tell us what you think.

Twitter Go to @PharmaTimes

Find a job

Website Search

Search News Search Magazine

Business Insight


Competitions News


International Clinical Researcher of the Year 2016

Book your tickets today!